Liquidia Stock Surges 37% Following $380.7M Patent Settlement

Key Facts

1Liquidia shares surged 37% following a patent settlement agreement with United Therapeutics.

2The settlement is valued at $380.7 million, resolving disputes over a lung disease drug.

Liquidia shares surged 37% following a patent settlement agreement with United Therapeutics. Barron's reported that the settlement is valued at $380.7 million, effectively resolving ongoing disputes over a drug designed to treat lung disease.

LQDA closed at $26.81 on October 13, 2026, while United Therapeutics (UTHR) closed at $543.40 on the same date. The agreement removes significant legal uncertainty for Liquidia, providing a clear commercial path for its treatment and a substantial cash inflow to support its growth strategy.